To validate and compare our findings in cutaneous melanoma we reanalyzed a scRNA+TCRαβ-seq dataset including immune and tumor cells from patients with uveal melanoma (n = 9)34, which has a lower mutation burden and immune checkpoint inhibitor therapy response rate than cutaneous melanoma35 but expresses also same MAAs like MART136 and has currently an approved anti-MAA TCR based therapy37. This evidence concerns the gene NAA10 and cutaneous melanoma.